There are few drugs approved by FDA that open old regulatory wounds like GlaxoSmithKline's Avandia.
The Type II diabetes therapy has been the subject of intense scrutiny by Congress and FDA ever since Cleveland Clinic cardiologist Steve Nissen published a meta-analysis in the New England...